"Effectiveness of Non-invasive Neuromodulation Treatment for Improving Sexual Satisfaction in Healthy Subjects.


European University


Not yet enrolling


Sexual Satisfaction


Device: Non-Invasive Neuromodulation (NESA)

Study type


Funder types



CI 240228, 2024-480

Details and patient eligibility


The main objectives of the programming with the XSignal device will be to influence the sexual satisfaction of the participants. As secondary objectives, the effectiveness of the XSignal device during a defined treatment period will be analyzed in terms of quality of life, pain, stress, anxiety, sexual function, sleep quality, cortisol, heart rate, blood pressure, respiratory rate, and body temperature of the same subjects, compared with a placebo group, observing the long-term influence of the results.

Full description

Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.


40 estimated patients




18 to 65 years old


Accepts Healthy Volunteers

Inclusion criteria

  • Subjects from 18 to 65 years
  • Sexually active
  • Signed consent form

Exclusion criteria

  • Diagnosed diseases.
  • Severe previous psychiatric conditions.
  • Medical contraindications that prevent the use of non-invasive neuromodulation therapy.
  • Having exercised in the hours prior to the NESA treatment.
  • Having consumed coffee or tobacco in the hours prior to the treatment.
  • Minors.
  • Individuals who have previously received any type of neuromodulation treatment.
  • Cancer.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Double Blind

40 participants in 2 patient groups, including a placebo group

Experimental group
T The total number of sessions to be conducted for each patient will be 10 sessions, spread over 5 weeks, which means a frequency of twice a week. Each NESA microcurrent session will last 60 minutes. A maximum time of 15 minutes will be allowed for connecting the patient at the beginning and for removing the device at the end. During the 10 sessions of the treatment, the programming will evolve to optimize the response. The directing electrode will be located throughout the treatment between the spinous processes of C6 and C7 to act generally on the individual, and in later sessions, the electrode will be placed in the abdominal area to cover the hypogastric plexus and at S2-S3 to influence the sacral plexus. The intensity will be set to Low (3 volts) in all sessions, following the Arndt-Schulz law. The other device parameters range between 100-900 microamperes and between 1.14 and 14.29 hertz, and are preset by each program
Device: Non-Invasive Neuromodulation (NESA)
Placebo Comparator group
Non-active Non-invasive Neuromodulation (NESA)
Device: Non-Invasive Neuromodulation (NESA)

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems